Fierce Healthcare

JULY 5, 2023

Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, payers and other industry players look to expand their businesses and gain a competitive edge.

Insurance 104

Insurance Hospitals 104

STAT

APRIL 24, 2024

Today we have some developments about Novo Nordisk’s insulin business, a side of the company that people don’t really talk about anymore, and some news about their GLP-1 business, a side that people can’t stop talking about. Want to stay on top of the science and politics driving biotech today?  Good morning!

102

102

Fierce Healthcare

NOVEMBER 1, 2023

Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry players look to expand their businesses and gain a competitive edge. Henry Ford Health's $10.5

52

52

Fierce Healthcare

SEPTEMBER 1, 2023

Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry players look to expand their businesses and gain a competitive edge. hospital group, NextGen Healthcare sale rumors and more merger and acquisition news from the month of August.

Hospitals 57

Hospitals 57

Fierce Pharma

SEPTEMBER 11, 2023

I am the Strategic Business Unit Head and Global Head of Mergers and Acquisitions for Life Sciences at Cognizant. | Gaurav Marya: Hi everyone. My name is Gaurav Marya.

73

73

Fierce Healthcare

OCTOBER 4, 2023

Healthcare mergers and acquisitions are in no short supply as providers, health tech companies, retailers and other industry players look to expand their businesses and gain a competitive edge.

52

52

Pharmaceutical Technology

JULY 25, 2023

Partnerships, mergers, business combinations, and acquisitions could all be on the horizon for the biotech.

52

52

STAT

SEPTEMBER 20, 2022

Justice Department’s legal challenge to UnitedHealth Group’s $13 billion acquisition of the technology company Change Healthcare.  UnitedHealth had already agreed to sell the business to TPG for $2.2 UnitedHealth had already agreed to sell the business to TPG for $2.2

Insurance 88

Insurance 88

pharmaphorum

NOVEMBER 24, 2020

A merger involving two US digital health specialists and a blank cheque company has created a telemedicine player, called UpHealth, that is valued at more than $1.3 The blank cheque company or ‘special purpose acquisition company’ (SPAC) that provides funding is GigCapital2, which raised $150 million in its public offering in June 2019.

Packaging 130

Packaging Compounding Insurance Patient Care 130

pharmaphorum

DECEMBER 28, 2022

This year, the predicted flurry of merger and acquisition (M&A) activity might not have materialised. But what steps can the smaller companies at the cutting edge take to make them acquisition-ready and maximise their value during this process? However, as we near the end of the year, there were some big moves.

Documentation 115

Documentation Pharmaceutical Companies Pharmaceutical Companies FDA 115

Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, the company, through Astellas US Holding’s wholly owned subsidiary Berry Merger Sub, will acquire all the outstanding Iveric Bio shares for $40.00 We believe that this acquisition will enable us to deliver greater VALUE to patients with ocular diseases at high risk of blindness.” in cash for each share.

FDA 111

FDA 111

Pharmaceutical Technology

JULY 26, 2022

NewAmsterdam Pharma has signed a definitive business combination agreement with special purpose acquisition company (SPAC) Frazier Lifesciences Acquisition (FLAC). It will take the total pro forma cash balance of the merged business to a minimum of $470m apart from a total enterprise value of $326m.

59

59

European Pharmaceutical Review

SEPTEMBER 4, 2023

billion acquisition of Horizon Therapeutics plc could bring. The proposed resolution “sends a clear signal that the FTC and its state partners will scrutinise pharmaceutical mergers that enable such practices,” Liu added. The FTC has settled on a proposed consent order with Amgen Inc. Divest to invest: the new normal in biopharma?

81

81

Pharmaceutical Technology

NOVEMBER 1, 2022

Intrinsic Medicine has signed a definitive business combination agreement with special purpose acquisition (SPAC) firm Phoenix Biotech Acquisition to create a public company. The merged business will use human milk biology for the treatment of Gut-Brain Axis (GBA) disorders. in cash held in trust to Intrinsic. .

Compounding 59

Compounding 59

Pharmaceutical Technology

APRIL 17, 2023

NKGen Biotech, a clinical-stage natural killer (NK) cell therapy firm, has signed a definitive agreement to combine its business operations with Graf Acquisition. The merger is scheduled to be completed by the third quarter of 2023. We believe that the business combination represents a key step in our overall growth strategy. “We

98

98

Pharmaceutical Technology

NOVEMBER 1, 2022

FEATURED COMPANIES COMMENDED : • Innovation • Product Launch • Safety VIEW PROFILE COMMENDED : • Business Expansion • Innovation • Investments VIEW PROFILE COMMENDED: • Social VIEW PROFILE. The Excellence Rankings celebrate the greatest achievements and innovations in the industry. What is M&A? Is your company ranked?

52

52

Pharmaceutical Technology

MAY 28, 2023

The $250m merger of Clearday and Viveon Health Acquisition and 98point6 was the industry’s largest disclosed deal. Analysis of the key themes driving M&A activity reveals that virtual care accounted for 6 pharmaceutical deals announced in Q1 2023, worth a total value of $426.2m.

52

52

Pharmaceutical Technology

OCTOBER 18, 2022

Oculis has signed a definitive business combination agreement with special purpose acquisition company (SPAC) European Biotech Acquisition (EBAC). The merged business is anticipated to have an enterprise value of nearly $220m following the closing of the transaction.

59

59

European Pharmaceutical Review

DECEMBER 30, 2023

The past 12 months has seen significant growth in global mergers and acquisitions (M&A) within the biopharma sector. With the patent cliff posing a significant challenge to biopharma companies, dealmaking is likely to evolve over the coming years, with bolt-on acquisitions expected to dominate.

102

102

Pharmaceutical Technology

MAY 26, 2023

Pharma company merger and acquisition (M&A) activity in the first half of 2023 has remained relatively low, consistent with the second half of last year, but investors predict deals will increase later in 2023. Experts at PWC, Goldman Sachs, and Morgan Stanley agree that pharma-related M&A is expected to pick up in 2023.

Packaging 52

Packaging 52

Pharmaceutical Technology

JULY 21, 2022

ZyVersa Therapeutics has signed a definitive business combination agreement with blank-check special purpose acquisition company (SPAC) Larkspur Health Acquisition. The post ZyVersa Therapeutics enters SPAC merger deal with Larkspur appeared first on Pharmaceutical Technology.

59

59

pharmaphorum

AUGUST 17, 2021

A complaint filed by the US Securities and Exchange Commission (SEC) today accuses Matthew Panuwat, the then-head of business development at Medivation, of buying sizeable stock options in rival cancer-focused biotech InCyte Corp in the days before the merger went through in September 2016. Matthew Panuwat.

52

52

Pharmaceutical Technology

JULY 11, 2022

Innoviva has signed a definitive merger agreement for the acquisition of all of the outstanding shares of La Jolla Pharmaceutical Company for $6.23 The boards of directors of Innoviva and La Jolla have granted unanimous approval for the acquisition. for each share in cash or an enterprise value of nearly $149m.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceutical Companies FDA 59

pharmaphorum

JUNE 20, 2022

The rumour was first published in the Wall Street Journal, which suggests that a takeover is just one option on the table, along with a marketing deal that would bind the two companies together without the risk of antitrust issues holding up or blocking a merger.

105

105

pharmaphorum

SEPTEMBER 30, 2021

billion, setting up what could be one of the largest biopharma acquisitions of 2021 so far. Merck said the two drugs will “complement and strengthen” its cardiovascular pipeline – which has been somewhat eclipsed by its vaccines and oncology businesses in recent years.

Vaccines 105

Vaccines 105

Roots Analysis

FEBRUARY 7, 2023

This not only enables them to attract more business opportunities from sponsors, but also grants them an edge over competing service provider entities. It is worth mentioning that in 2021, more than 12 acquisitions have taken place within this industry. The post Rising Demand for Medical Devices CROs appeared first on Blog.

40

40

pharmaphorum

MAY 31, 2021

Digital health player Babylon Health is exploring a merger with a so-called ‘blank cheque’ company as a route to a public listing, according to a Swedish investment group. The post Babylon Health may go public via blank cheque company merger; report appeared first on.

59

59

pharmaphorum

AUGUST 30, 2022

If it goes through, the merger will add Diurnal’s approved treatments – Alkindi (hydrocortisone granule capsules) for paediatric adrenal insufficiency and Efmody (hydrocortisone modified-release hard capsules) for congenital adrenal hyperplasia (CAH) – to Neurocrine’s commercial portfolio.

99

99

pharmaphorum

SEPTEMBER 6, 2022

The EU has blocked the merger of Illumina and Grail, saying the deal would stifle innovation in blood-based diagnostics for cancer diagnostics, just days after a bid by the US authorities to do likewise was blocked in the courts. billion merger would squeeze other players in the liquid biopsy category out of the market.

52

52

Pharmaceutical Technology

DECEMBER 1, 2022

Liminatus Pharma has entered a definitive business combination agreement with special purpose acquisition company (SPAC) Iris Acquisition to create a business with a pro forma enterprise value of nearly $334m. These funds are expected to back the further business growth plan of Liminatus.

Immunization 52

Immunization Vaccines Communication 52

Pharmaceutical Technology

DECEMBER 19, 2022

Business Expansion. Business Expansion is one of our largest categories and looks at the core functions of business operations within the sector. What all the ranked entities have in common is the demonstration of new concepts not just within their own business but in the sector as a whole. Environmental.

52

52

European Pharmaceutical Review

APRIL 17, 2023

The report noted that to strengthen their market position, leading companies have implemented tactics such as mergers and acquisitions, increasing investment in R&D, forming collaborations and partnerships, expanding their business into new regions and introducing new products.

Dosage 90

Dosage Compounding 90

European Pharmaceutical Review

APRIL 5, 2023

The collaboration will be the first fully integrated biopharmaceutical and supply chain solution for the business. Partnerships, collaborations, mergers and acquisitions within the field are also helping to increase business. billion in 2031. This translates into a promising compound annual growth rate (CAGR) of 11.2

Packaging 75

Packaging Compounding 75

pharmaphorum

SEPTEMBER 18, 2020

We take a look at the company’s story, from its creation as a merger of two equals, to its recent major restructuring and its drives in cutting-edge oncology and COVID-19. The fusion between Swedish pharmaceutical company, Astra AB, and UK-based Zeneca Group plc, was one of the largest-ever European mergers at the time.

Vaccines 116

Vaccines Pharmaceutical Companies Pharmaceutical Companies FDA 116

pharmaphorum

JULY 30, 2021

The telehealth specialist said it is paying a combined $320 million for the two business, which will be paid for using a mix of stock and cash. The two businesses will add around $15 million to its revenues this year, doubling to $30 million in 2022, said Amwell, and will also expand its client base.

Hospitals 95

Hospitals 95

pharmaphorum

NOVEMBER 7, 2022

With more than a decade of experience leading and scaling managed care organisations, Grabski is a seasoned business leader and finance executive. He has also served as VP of Strategy and Execution, primarily responsible for adapting UHC’s Medicare Advantage business to the changes from the ACA. Ben Grabski, Lumeris.

Pharmaceutical Companies 103

Pharmaceutical Companies Pharmaceutical Companies 103

pharmaphorum

JUNE 19, 2022

Telus has been building its health business since the late 2000s, starting with the acquisition of electronic health record company Emergis in 2008 and since expanding into health benefits management, telemedicine, and electronic prescribing. Its platform had around 7.1

52

52